text Therapeutics (US:CNTX)2022-03-22 16:00Financial Position - The company reported cash and cash equivalents of $49.6 million as of December 31, 2021[550] - The company has cash and cash equivalents that would not be materially affected by an immediate 10% change in interest rates[550] Profitability and Business Viability - The company has never been profitable and may never achieve or maintain profitability[23] - The company has a limited operating history, making it difficult to evaluate its current business and future prospects[23] Product Development and Regulatory Approval - The company is dependent on the successful development and regulatory approval of its therapeutic product candidates, ONA-XR and CLDN6xCD3 bsAb, which are in early stages of development[23] - The company anticipates that CLDN6xCD3 bsAb will be regulated as biological products, which may subject them to competition sooner than expected[25] - The company may face significant delays in the clinical development and regulatory approval of its product candidates due to the lengthy FDA approval process[25] Collaboration and Funding - The company expects to rely on collaborations with third parties for research, development, and commercialization activities[23] - The company has plans to seek additional capital in the future through equity and/or debt financings[23] Market Opportunity - The company estimates the size of the market opportunity for its product candidates, including the number of patients suffering from targeted diseases[23]